MX2021004819A - Composiciones y metodos para tratar lesiones cerebrales. - Google Patents
Composiciones y metodos para tratar lesiones cerebrales.Info
- Publication number
- MX2021004819A MX2021004819A MX2021004819A MX2021004819A MX2021004819A MX 2021004819 A MX2021004819 A MX 2021004819A MX 2021004819 A MX2021004819 A MX 2021004819A MX 2021004819 A MX2021004819 A MX 2021004819A MX 2021004819 A MX2021004819 A MX 2021004819A
- Authority
- MX
- Mexico
- Prior art keywords
- brain injury
- methods
- compositions
- treating brain
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754750P | 2018-11-02 | 2018-11-02 | |
| PCT/US2019/059446 WO2020092937A1 (en) | 2018-11-02 | 2019-11-01 | Compositions and methods for treating brain injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004819A true MX2021004819A (es) | 2021-06-08 |
Family
ID=70459352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004819A MX2021004819A (es) | 2018-11-02 | 2019-11-01 | Composiciones y metodos para tratar lesiones cerebrales. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200140533A1 (https=) |
| EP (1) | EP3873525B1 (https=) |
| JP (1) | JP7499760B2 (https=) |
| AU (1) | AU2019370485B2 (https=) |
| CA (1) | CA3118453A1 (https=) |
| ES (1) | ES3015004T3 (https=) |
| MX (1) | MX2021004819A (https=) |
| WO (1) | WO2020092937A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3019240T3 (da) | 2013-07-09 | 2024-06-03 | Annexon Inc | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf |
| AU2021278819A1 (en) * | 2020-05-05 | 2022-11-24 | Annexon, Inc. | Compositions and methods for treating epilepsy |
| KR20230039734A (ko) | 2020-07-23 | 2023-03-21 | 오타이르 프로테나 리미티드 | 항-Aβ 항체 |
| IL300376A (en) * | 2020-08-06 | 2023-04-01 | Bioverativ Usa Inc | Inflammatory cytokines and fatigue in subjects with complement-mediated disease |
| US20240420490A1 (en) * | 2021-10-19 | 2024-12-19 | Denali Therapeutics Inc. | Microglial cell morphometry |
| US12486322B2 (en) * | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
| CN121197154A (zh) * | 2025-11-13 | 2025-12-26 | 首都医科大学附属北京天坛医院 | Mac-1激动剂在制备治疗和/或缓解脑出血药物中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| WO1995005864A1 (en) | 1993-08-27 | 1995-03-02 | Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Convection-enhanced drug delivery |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| CA2502413A1 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| CN101120021A (zh) | 2004-12-31 | 2008-02-06 | 基因技术公司 | 结合br3的多肽及其用途 |
| ES2447844T3 (es) | 2008-04-03 | 2014-03-13 | Vib Vzw | Anticuerpos de dominio individual capaces de modular la actividad BACE1 |
| AU2009283889A1 (en) * | 2008-08-20 | 2010-02-25 | The Trustees Of Columbia University In The City Of New York | Complement inhibitors for treatment of injury from intracerebral hemorrhage |
| WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| US9181535B2 (en) | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
| EP3722320A3 (en) * | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP2997045A4 (en) * | 2013-05-15 | 2016-11-23 | Annexon Inc | ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF |
| EP3004170A1 (en) | 2013-05-28 | 2016-04-13 | VIB vzw | Single domain antibodies against sod1 and their use in medicine |
| DK3019240T3 (da) * | 2013-07-09 | 2024-06-03 | Annexon Inc | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf |
| SI3215527T1 (sl) * | 2014-11-05 | 2025-04-30 | Annexon, Inc. | Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba |
| SG11201900123TA (en) * | 2016-07-19 | 2019-02-27 | Annexon Inc | Compositions and methods for treating frontotemporal dementia |
-
2019
- 2019-11-01 JP JP2021523487A patent/JP7499760B2/ja active Active
- 2019-11-01 ES ES19878411T patent/ES3015004T3/es active Active
- 2019-11-01 CA CA3118453A patent/CA3118453A1/en active Pending
- 2019-11-01 MX MX2021004819A patent/MX2021004819A/es unknown
- 2019-11-01 AU AU2019370485A patent/AU2019370485B2/en active Active
- 2019-11-01 EP EP19878411.8A patent/EP3873525B1/en active Active
- 2019-11-01 WO PCT/US2019/059446 patent/WO2020092937A1/en not_active Ceased
- 2019-11-01 US US16/671,920 patent/US20200140533A1/en not_active Abandoned
-
2023
- 2023-08-04 US US18/230,480 patent/US20240083989A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019370485A1 (en) | 2021-05-13 |
| EP3873525A1 (en) | 2021-09-08 |
| AU2019370485B2 (en) | 2025-12-18 |
| US20200140533A1 (en) | 2020-05-07 |
| ES3015004T3 (en) | 2025-04-28 |
| JP7499760B2 (ja) | 2024-06-14 |
| EP3873525A4 (en) | 2022-07-13 |
| WO2020092937A1 (en) | 2020-05-07 |
| JP2022512863A (ja) | 2022-02-07 |
| CA3118453A1 (en) | 2020-05-07 |
| US20240083989A1 (en) | 2024-03-14 |
| EP3873525B1 (en) | 2024-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004819A (es) | Composiciones y metodos para tratar lesiones cerebrales. | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| PH12022550098A1 (en) | Parp1 inhibitors | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| MX2018010374A (es) | Inhibidores del enlace proteína-proteína de wdr5. | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| FR3034993B1 (fr) | Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| MX2019008875A (es) | Composiciones de inhibidor del canal crac. | |
| MY202884A (en) | Compounds useful in hiv therapy | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| MX2017015012A (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
| SA522431538B1 (ar) | طُرق وتركيبات لعلاج تساقط الشعر | |
| PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| MX2018008555A (es) | Uso de ayuno simulado de largo plazo como tratamiento dietetico para mieloma multiple y otros canceres. | |
| WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
| PH12021552133A1 (en) | Aromatic derivatives, preparation methods, and medical uses thereof | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| MX2023004881A (es) | Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca. |